NL-OMON53777
Recruiting
Not Applicable
HYpofractionated, Dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma - HYDRA trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Head and neck squamous cell carcinoma
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 154
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with squamous cell carcinoma of the oropharynx, hypopharynx and larynx
- •who are eligible for curative intent proton or photon therapy, with or without
- •concurrent radiosensitizer
Exclusion Criteria
- •Previously treated by irradiation in the head and neck region
- •Chronic inflammatory disease or immune disorders
- •Other malignant disease (unless in situ carcinoma or BCC) within the last 2
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Intensity-modulated, hypofractionated radiotherapy with scanning beam protons for locally advanced carcinoma of the prostate and localized carcinoma of the prostate with risk factors - a phase II studyC61Malignant neoplasm of prostateDRKS00011912Westdeutsches Protonentherapiezentrum Essen (WPE)133
Recruiting
Phase 3
Standard moderately hypofractionated radiotherapy vs. ultra-hypofractionated focal lesion ablative microboost in prostate cancer, Hypo-FLAME 3.0prostate cancer10038597NL-OMON56327Antoni van Leeuwenhoek Ziekenhuis352
Active, not recruiting
Not Applicable
Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancerKCT0005443ational Cancer Center35
Not yet recruiting
Phase 2
Higher cumulative dose, 6days/week vs standard, 5days/week moderately hypofractionated palliative radiotherapy with concurrent chemotherapy in locally advanced head and neck carcinoma.CTRI/2023/10/058621AIIMS, New Delhi
Recruiting
Phase 2
Two-fraction Ultra-hypofractionated Radiotherapy with Focal Boost for low- and intermediate risk, localized prostate cancer (TURBO):phase II, randomized controlled clinical trialprostate adenocarcinomaprostate cancer100276561001818810036958NL-OMON56580niversitair Medisch Centrum Utrecht160